Page 13 - Read Online

Mason What clinicians should want from scientists

Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis 2012;367:1187-97.
ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, 23. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger
Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang
D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS.
Investigators. Enzalutamide in metastatic prostate cancer before Chemohormonal therapy in metastatic hormone-sensitive prostate
chemotherapy. N Engl J Med 2014;371:424-33. cancer. N Engl J Med 2015;373:737-46.
22. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit 24. Galazi M, Rodriguez-Vida A, Ng T, Mason M, Chowdhury S.
R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon Precision medicine for prostate cancer. Expert Rev Anticancer Ther
A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, 2014;14:1305-15.
Seely L, de Bono JS; AFFIRM Investigators. Increased survival with 25. Packer JR, Maitland NJ. The molecular and cellular origin of human
enzalutamide in prostate cancer after chemotherapy. N Engl J Med prostate cancer. Biochim Biophys Acta 2016;1863:1238-60.

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ November 17, 2017 277